Neuroblastoma risk level grading marker and application thereof

The invention belongs to the technical field of molecular diagnosis, and particularly relates to a group of neuroblastoma risk grading markers and application thereof. The invention provides application of a group of markers in preparation of a neuroblastoma risk grading medicament, the markers are...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LI LIFENG, GAO JING, ZHANG FEI, QIN XUEYI, HOU LIGONG, YU ZHIDAN, LIANG YING, SUN MENG, ZHANG MENGXIN, ZHANG YAODONG, DU BANG, ZHANG XIANWEI, ZHANG WANCUN
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention belongs to the technical field of molecular diagnosis, and particularly relates to a group of neuroblastoma risk grading markers and application thereof. The invention provides application of a group of markers in preparation of a neuroblastoma risk grading medicament, the markers are gene markers, and the markers are one or a combination of more than two markers selected from FABP4, HBB, MGST1, S100A9, CXCL9, SERPINE1, MFAP4, HMOX1, CD36, CIP2A, UBE2C, KNTC1, ALK, IL10, ALPL, IGF2, NXN, ITGA1, CDK2, CHL1, TCF7L2, UNC5D, ERBB3 and CGA. The invention also comprises a primer combination for quantitatively detecting the marker by adopting fluorescence, and an acquisition method of the marker. According to the invention, a method based on reverse transcription chain reaction (RT-PCR) is adopted to establish an HR-NB risk classification diagnosis model based on non-invasive plasma. The early diagnosis model based on the candidate biomarkers is of great significance to robust risk rating of HR-NB and